JP7071917B2 - ヘテロ芳香族ｎｍｄａ受容体モジュレーターおよびその使用 - Google Patents

ヘテロ芳香族ｎｍｄａ受容体モジュレーターおよびその使用 Download PDF

Info

Publication number
JP7071917B2
JP7071917B2 JP2018529995A JP2018529995A JP7071917B2 JP 7071917 B2 JP7071917 B2 JP 7071917B2 JP 2018529995 A JP2018529995 A JP 2018529995A JP 2018529995 A JP2018529995 A JP 2018529995A JP 7071917 B2 JP7071917 B2 JP 7071917B2
Authority
JP
Japan
Prior art keywords
mmol
alkyl
phenyl
group
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018529995A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018536685A5 (enExample
JP2018536685A (ja
Inventor
アンダーソン，ディヴィッド，アール．
フォルクマン，ロバート，エー．
メニティ，フランク，エス．
ファンガー，クリストファー
Original Assignee
カデント セラピューティクス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by カデント セラピューティクス，インコーポレーテッド filed Critical カデント セラピューティクス，インコーポレーテッド
Publication of JP2018536685A publication Critical patent/JP2018536685A/ja
Publication of JP2018536685A5 publication Critical patent/JP2018536685A5/ja
Application granted granted Critical
Publication of JP7071917B2 publication Critical patent/JP7071917B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
JP2018529995A 2015-12-09 2016-12-09 ヘテロ芳香族ｎｍｄａ受容体モジュレーターおよびその使用 Active JP7071917B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562265182P 2015-12-09 2015-12-09
US62/265,182 2015-12-09
PCT/US2016/065852 WO2017100591A1 (en) 2015-12-09 2016-12-09 Heteroaromatic nmda receptor modulators and uses thereof

Publications (3)

Publication Number Publication Date
JP2018536685A JP2018536685A (ja) 2018-12-13
JP2018536685A5 JP2018536685A5 (enExample) 2020-01-23
JP7071917B2 true JP7071917B2 (ja) 2022-05-19

Family

ID=57681781

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018529995A Active JP7071917B2 (ja) 2015-12-09 2016-12-09 ヘテロ芳香族ｎｍｄａ受容体モジュレーターおよびその使用

Country Status (15)

Country Link
US (3) US10626122B2 (enExample)
EP (1) EP3386591B1 (enExample)
JP (1) JP7071917B2 (enExample)
CY (1) CY1123359T1 (enExample)
DK (1) DK3386591T3 (enExample)
ES (1) ES2821010T3 (enExample)
HR (1) HRP20201522T1 (enExample)
HU (1) HUE051395T2 (enExample)
LT (1) LT3386591T (enExample)
PL (1) PL3386591T3 (enExample)
PT (1) PT3386591T (enExample)
RS (1) RS60834B1 (enExample)
SI (1) SI3386591T1 (enExample)
SM (1) SMT202000534T1 (enExample)
WO (1) WO2017100591A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3386591T3 (da) 2015-12-09 2020-09-28 Cadent Therapeutics Inc Heteroaromatic nmda receptor modulators and uses thereof
US10500205B2 (en) 2015-12-09 2019-12-10 Cadent Therapeutics, Inc. Thienopyrimidinone NMDA receptor modulators and uses thereof
CA3047403A1 (en) 2016-12-22 2018-06-28 Cadent Therapeutics, Inc. Nmda receptor modulators and uses thereof
HUE062566T2 (hu) 2018-08-03 2023-11-28 Novartis Ag Heteroaromás NMDA receptor modulátorok és alkalmazásaik
US11358971B2 (en) * 2019-07-03 2022-06-14 H. Lundbeck A/S Prodrugs of modulators of the NMDA receptor
IN202011027502A (enExample) * 2020-06-29 2021-12-31 Council Scient Ind Res
WO2025019109A1 (en) * 2023-07-17 2025-01-23 Neumora Therapeutics, Inc. Modulators of nmda receptors and related products and methods

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008532981A (ja) 2005-03-11 2008-08-21 ナームローゼ・フエンノートチヤツプ・オルガノン ２−（４−オキソ−４ｈ−キナゾリン−３−イル）アセトアミド及びバソプレッシンｖ３拮抗薬としてのこの使用
WO2008138126A1 (en) 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Bicyclic pyrimidine derivatives as calcium channel blockers
JP2010502746A (ja) 2006-09-11 2010-01-28 ナームローゼ・フエンノートチヤツプ・オルガノン キナゾリノンおよびイソキノリノンアセトアミド誘導体
JP2010502745A (ja) 2006-09-11 2010-01-28 ナームローゼ・フエンノートチヤツプ・オルガノン ２−（１−オキソ−１ｈ−イソキノリン−２−イル）アセトアミド誘導体
WO2010139483A1 (en) 2009-06-04 2010-12-09 Merz Pharma Gmbh & Co. Kgaa Glycine b antagonists
JP2013507417A (ja) 2009-10-13 2013-03-04 エム・エス・ディー・オス・ベー・フェー アセチルコリン受容体に関連する疾患の処置のための縮合アジン誘導体
JP2014517833A (ja) 2011-05-10 2014-07-24 ギリアード サイエンシーズ， インコーポレイテッド イオンチャネルモジュレーターとしての縮合複素環式化合物

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1067079A (en) 1976-07-22 1979-11-27 Yamanouchi Pharmaceutical Co. Nitrogen-containing heterobicyclic compounds
FR2549834B1 (fr) 1983-07-25 1985-10-18 Sanofi Sa Derives de triazolo-pyrimidine, leur procede de preparation et leur application therapeutique en tant que tonicardiaques
US4921854A (en) 1986-12-30 1990-05-01 Egis Gyogyszergyar Condensed thiazolopyrimidine, pyrimido-thiazine or thiazepine pyrimidine compounds
US5298502A (en) 1988-12-12 1994-03-29 Fmc Corporation Method and composition for photodynamic treatment and detection of tumors
WO1994027975A1 (de) 1993-05-21 1994-12-08 Pentapharm Ag 3-(mercaptoalkyl)- bzw. 3-(alkylthioalkyl)-pyrimidin-2,4 (1h, 3h)-dione
CA2257950A1 (en) 1996-06-28 1998-01-08 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
US6339093B1 (en) 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives
WO2002000629A1 (en) 2000-06-26 2002-01-03 Merck & Co., Inc. Iminopyrimidine nmda nr2b receptor antagonists
US6878743B2 (en) 2001-09-18 2005-04-12 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
AR038118A1 (es) 2002-01-14 2004-12-29 Upjohn Co Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
CN101035765B (zh) 2004-07-13 2010-10-13 弗·哈夫曼-拉罗切有限公司 磺酰胺衍生物
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
EP2425840B1 (en) 2006-12-15 2015-04-08 Abraxis BioScience, Inc. Triazine derivatives and their therapeutical applications
EP1939187A1 (en) 2006-12-20 2008-07-02 Sanofi-Aventis Substituted heteroaryl pyridopyrimidone derivatives
US8183276B2 (en) 2007-02-08 2012-05-22 Christian Fischer Therapeutic agents
US9034907B2 (en) 2007-04-18 2015-05-19 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2008289573B2 (en) 2007-08-21 2013-05-16 Merck Sharp & Dohme Corp. Heterocyclic compounds as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
TW200934497A (en) 2007-11-13 2009-08-16 Organon Nv Heterocyclic derivatives
ES2586459T3 (es) 2008-05-01 2016-10-14 Glaxosmithkline Llc Quinolinas y análogos relacionados como moduladores de sirtuina
MX2010012961A (es) 2008-05-29 2011-03-03 Sirtris Pharmaceuticals Inc Star Imidazopiridina y analogos relacionados como moduladores de sirtuina.
EP2138494A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted alkyl pyrimidin-4-one derivatives
JP5758292B2 (ja) 2008-07-03 2015-08-05 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン調節薬としてのベンズイミダゾールおよび関連する類似体
CN101628913B (zh) 2008-07-18 2013-01-23 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
AU2009295946B2 (en) 2008-09-29 2013-03-21 Sirtris Pharmaceuticals, Inc. Chromenone analogs as sirtuin modulators
HRP20150355T1 (hr) 2009-01-12 2015-06-19 Pfizer Limited Sulfonamidni derivati
EP2411370B1 (en) 2009-03-27 2015-04-22 AbbVie Inc. Compounds as cannabinoid receptor ligands
TW201116532A (en) 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
JP5871897B2 (ja) 2010-03-26 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジルトリアゾール
US9290507B2 (en) 2010-03-26 2016-03-22 Boehringer Ingelheim International Gmbh B-RAF kinase inhibitors
EP2593106A4 (en) 2010-07-16 2014-01-01 Univ Rockefeller ORGANIC CONNECTIONS
JP2013540145A (ja) 2010-10-21 2013-10-31 ウニベルシテート デス ザールランデス コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤
US20120165330A1 (en) 2010-12-22 2012-06-28 Sirtris Pharmaceuticals, Inc. Quinazolinone and related analogs as sirtuin modulators
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2013048928A1 (en) 2011-09-27 2013-04-04 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
EP2760840B1 (en) 2011-09-30 2015-08-12 Bristol-Myers Squibb Company Quinolinone carboxamide inhibitors of endothelial lipase
US8993557B2 (en) 2011-09-30 2015-03-31 Bristol-Myers Squibb Company Pyridinedione carboxamide inhibitors of endothelial lipase
CN102336768A (zh) 2011-10-24 2012-02-01 中国科学院上海有机化学研究所 N’-芳亚甲基-2-(4-氧代噻吩[2,3-d]嘧啶-3-基)乙酰腙类化合物、制备方法和用途
TWI701253B (zh) 2011-11-11 2020-08-11 美商基利阿波羅有限責任公司 Ａｃｃ抑制劑及彼等之用途
EA029542B1 (ru) 2012-02-10 2018-04-30 ПиТиСи ТЕРАПЬЮТИКС, ИНК. ПРОИЗВОДНЫЕ 4Н-ПИРИДО[1,2-а]ПИРИМИДИН-4-ОНА ДЛЯ ЛЕЧЕНИЯ СПИНАЛЬНОЙ МЫШЕЧНОЙ АТРОФИИ
WO2014066743A1 (en) 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2014179144A1 (en) 2013-04-29 2014-11-06 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
MX362582B (es) 2013-06-28 2019-01-24 Beigene Ltd Compuestos triciclicos fusionados de urea como inhibidores de raf quinasa y/o dimero de raf quinasa.
WO2015007453A1 (en) 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
US20150141433A1 (en) 2013-09-26 2015-05-21 Mnemosyne Pharmaceuticals, Inc. N-arylmethyl sulfonamide negative modulators of nr2a
PT3055315T (pt) 2013-10-11 2018-10-25 Hoffmann La Roche Tiazolopirimidonas enquanto moduladores da atividade do recetor nmda
WO2015064714A1 (ja) 2013-10-31 2015-05-07 国立大学法人東京大学 オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体
CN103664877A (zh) 2013-12-25 2014-03-26 重庆医药工业研究院有限责任公司 一种喹啉衍生物、其制备方法和应用
EP3191459A1 (en) * 2014-09-05 2017-07-19 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
WO2016081649A1 (en) 2014-11-18 2016-05-26 Emory University Thieno[2,3-d]pyrimidin-4-one derivatives as nmdar modulators and uses related thereto
UA120647C2 (uk) 2015-04-15 2020-01-10 Ф. Хоффманн-Ля Рош Аг Піридопіримідинони та їх застосування як модуляторів рецептора n-метил-d-аспартату
KR20180102052A (ko) 2015-10-16 2018-09-14 노오쓰웨스턴 유니버시티 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용
DK3386591T3 (da) 2015-12-09 2020-09-28 Cadent Therapeutics Inc Heteroaromatic nmda receptor modulators and uses thereof
US10500205B2 (en) 2015-12-09 2019-12-10 Cadent Therapeutics, Inc. Thienopyrimidinone NMDA receptor modulators and uses thereof
WO2017188694A1 (ko) 2016-04-25 2017-11-02 이뮤노메트테라퓨틱스 인코포레이티드 질소를 포함하는 헤테로아릴 화합물 및 이의 용도
WO2018026371A1 (en) 2016-08-04 2018-02-08 Sunovion Pharmaceuticals Inc. Dual nav1.2/5ht2a inhibitors for treating cns disorders
CA3047403A1 (en) 2016-12-22 2018-06-28 Cadent Therapeutics, Inc. Nmda receptor modulators and uses thereof
SMT202200011T1 (it) 2017-09-27 2022-03-21 Incyte Corp Sali di derivati di pirrolotriazina utili come inibitori di tam
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
HUE062566T2 (hu) 2018-08-03 2023-11-28 Novartis Ag Heteroaromás NMDA receptor modulátorok és alkalmazásaik

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008532981A (ja) 2005-03-11 2008-08-21 ナームローゼ・フエンノートチヤツプ・オルガノン ２−（４−オキソ−４ｈ−キナゾリン−３−イル）アセトアミド及びバソプレッシンｖ３拮抗薬としてのこの使用
JP2010502746A (ja) 2006-09-11 2010-01-28 ナームローゼ・フエンノートチヤツプ・オルガノン キナゾリノンおよびイソキノリノンアセトアミド誘導体
JP2010502745A (ja) 2006-09-11 2010-01-28 ナームローゼ・フエンノートチヤツプ・オルガノン ２−（１−オキソ−１ｈ−イソキノリン−２−イル）アセトアミド誘導体
WO2008138126A1 (en) 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Bicyclic pyrimidine derivatives as calcium channel blockers
WO2010139483A1 (en) 2009-06-04 2010-12-09 Merz Pharma Gmbh & Co. Kgaa Glycine b antagonists
JP2013507417A (ja) 2009-10-13 2013-03-04 エム・エス・ディー・オス・ベー・フェー アセチルコリン受容体に関連する疾患の処置のための縮合アジン誘導体
JP2014517833A (ja) 2011-05-10 2014-07-24 ギリアード サイエンシーズ， インコーポレイテッド イオンチャネルモジュレーターとしての縮合複素環式化合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALMASI, J. et al.，Characterization of potential NMDA and cholecystokinin antagonists II. Lipophilicity studies on 2-methyl-4-oxo-3H-quinazoline-3-alkyl-carboxylic acid derivatives，International Journal of Pharmaceutics，1999年，180(1)，pp. 13-22
NAPIER, S. E. et al.，Synthesis and SAR studies of novel 2-(6-aminomethylaryl-2-aryl-4-oxo-quinazolin-3(4H)-yl)acetamide Vasopressin V1b receptor antagonists，Bioorganic & Medicinal Chemistry Letters ，2011年，21(12)，pp. 3813-3817
NERKAR, A. G. et al.，In silico design, synthesis and pharmacological screening of novel mono and di-bromo quinazolinone derivatives as NMDA receptor antagonists for anticonvulsant activity，International Journal of Pharmacy and Pharmaceutical Sciences，2013年，5(1)，pp. 331-335
REGISTRY（STN）[online]，掲載日：2007年11月23日，検索日：2020年10月22日，CAS登録番号：955837-77-1, 955839-24-4, 955818-38-9その他多数

Also Published As

Publication number Publication date
US20180362541A1 (en) 2018-12-20
SI3386591T1 (sl) 2020-11-30
US20210107916A1 (en) 2021-04-15
EP3386591B1 (en) 2020-06-24
WO2017100591A1 (en) 2017-06-15
SMT202000534T1 (it) 2020-11-10
LT3386591T (lt) 2020-10-12
EP3386591A1 (en) 2018-10-17
US12162890B2 (en) 2024-12-10
US20230023543A1 (en) 2023-01-26
HRP20201522T1 (hr) 2020-12-11
US11236104B2 (en) 2022-02-01
HUE051395T2 (hu) 2021-03-01
US10626122B2 (en) 2020-04-21
PT3386591T (pt) 2020-10-01
JP2018536685A (ja) 2018-12-13
RS60834B1 (sr) 2020-10-30
DK3386591T3 (da) 2020-09-28
CY1123359T1 (el) 2021-12-31
ES2821010T3 (es) 2021-04-23
PL3386591T3 (pl) 2021-02-22

Similar Documents

Publication Publication Date Title
JP7071917B2 (ja) ヘテロ芳香族ｎｍｄａ受容体モジュレーターおよびその使用
KR101652189B1 (ko) ＴＲＫ 키나아제 억제제로서 치환된 피라졸로［１,５­ａ］ 피리미딘 화합물
US8962596B2 (en) 5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases
KR102354472B1 (ko) Ｊａｋ１ 저해제로서의 피페리딘­４­일 아제티딘 유도체
KR101851130B1 (ko) Ｃｋ2 억제제로서 피라졸로피리미딘 및 관련된 헤테로사이클
TW202246255A (zh) Ｃｄｋ抑制劑及其使用方法
KR20240044412A (ko) Dna 폴리머라제 세타 억제제로서의 o-연결된 티아디아졸릴 화합물
JP7257387B2 (ja) スピロ環化合物並びにその作製及び使用方法
KR20230003161A (ko) 브루톤의 티로신 키나제(btk) 억제제와 e3 리가제 리간드의 접합에 의한 btk의 분해 및 사용 방법
TW201326173A (zh) ５，７－經取代之－咪唑并［１，２－ｃ］嘧啶
JP2021510158A (ja) Ｍａｇｌ阻害剤としてのオクタヒドロピリド［１，２−アルファ］ピラジン
KR20160086930A (ko) 피롤로피롤론 유도체 및 bet 억제제로서의 그의 용도
JP2019534324A (ja) Ｐｄｅ１阻害剤としてのイミダゾピラジノン、ピラゾロピリミジノンおよびピラゾロピリジノン
TW202440111A (zh) 作為ｗｒｎ抑制劑之雜環化合物
JP2025503463A (ja) ブルトン型チロシンキナーゼ（ｂｔｋ）阻害剤をｅ３リガーゼリガンドにコンジュゲートすることによるｂｔｋの分解及び使用方法
WO2017100593A1 (en) Thienopyrimidinone nmda receptor modulators and uses thereof
JP7611900B2 (ja) 縮合複素環化合物
TWI902789B (zh) 藉由軛合ｂｔｋ抑制劑與ｅ３連接酶配位基降解布魯頓氏酪胺酸激酶（ｂｔｋ）及其使用方法
HK1213885B (en) Imidazo-triazine derivatives as pde10 inhibitors
HK1213885A1 (zh) 作爲pde10抑制剂的咪唑并-三嗪衍生物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191205

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220419

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220509

R150 Certificate of patent or registration of utility model

Ref document number: 7071917

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250